On September 18, METIS TECHBIO-P rose 8.56% in regular trading, trading at HK$17.22/share, with turnover of approximately HK$34.92 million. The stock extended gains following the continued fermentation of its recently announced strategic partnership.

On the news front, the company recently signed a joint venture agreement with Joinn Biologics to co-establish a new entity named ZhaoTai ZhiYao, aimed at building an mRNA drug innovation R&D and industrialization manufacturing platform. The first collaborative project has already been initiated. Under the agreement, METIS TECHBIO-P will contribute upstream design and delivery capabilities through its NanoForge platform, which has achieved targeted delivery to eight key organs and tissues in the human body. The announcement initially sparked a surge of over 14% on September 17, and buying momentum has carried into the following session.

The company reported H1 revenue of RMB 154 million, representing a year-over-year increase of over 133 times, while adjusted net losses narrowed by 56.4%. Its proprietary AiTEM platform has been deployed at Hengrui Medicine, and NanoForge commercialization continues to accelerate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)